Medicare AdvantageCoverageMedium impact
MA08.145a, Sutimlimab-jome (Enjaymo)
Independence Blue Cross·Hematology, Rheumatology, Oncology·Pharmacy
Effective date
Dec 10, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.145a for Sutimlimab-jome (Enjaymo) has been reissued with an effective date of December 10, 2025. This is a pharmacy policy update that may affect coverage, prior authorization, or billing requirements for this specialty medication used to treat certain autoimmune conditions.
Action Required
By December 10, 2025: Review the complete MA08.145a policy at the provided URL to understand specific coverage changes for Sutimlimab-jome (Enjaymo). Update prior authorization workflows and billing procedures as specified in the full policy. Notify providers who may prescribe this medication about any new requirements.